Board

PER LANGÖ

Chairman
Chairman since October 2023
Per Langö

  • Born: 1969
  • Education: MSc and BSc Uppsala University
  • Experience: Per has extensive international experience in the medical device and pharmaceutical industry. He has worked at Pharmacia & Upjohn, Q-Med, Galderma and Nestlé Skin Health. He has previously been CEO of Palette Life Sciences, which he co-founded in 2018, and today as CEO of GT Medical Technologies. His experience includes leadership, strategy, commercialization, business development and financing.
  • Other ongoing assignments: CEO GT Medical Technologies and alternate board member in Nordisk Medicin & Teknik AB.
  • Holdings: No holdings 

Independent in relation to the Company and its management and the Company's major shareholders.

PAUL DE POTOCKI

Board member
Board member since Ocotber 2023
thumbnail_Paul web

  • Born: 1962
  • Education: MSc from the Royal Institute of Technology in Stockholm, and an MBA from the London School of Economics
  • Experience: Paul has 28 years of experience in international corporate leadership, commercial operations, business & corporate development and financial management in life sciences companies. He has served as President and Chief Executive Officer of several public and private Med Tech and Pharma companies, and as Board Director of Palette Life Sciences, Asarina Pharma and Athera Biotechnologies. Paul has also served as Global Vice President of Commercial Operations at Biovitrum, FreseniusKabi and Pharmacia & Upjohn.
  • Other ongoing assignments: Chairman of the board Asarina Pharma AB
  • Holdings: No holdings 

Independent in relation to the Company and its management and the Company's major shareholders.

MARIANNE ÖSTLUND

Board member
Board member since 2020

  • Born: 1964
  • Education: Gothenburg School of Economics.
  • Experience: Solid experience in marketing and PR at national and international levels. She has many years of experience in board assignments by both listed and unlisted companies as well as associations. She also has valuable expertise from political work and lobbying at municipal, county and national levels. Deep knowledge of medical technology, pharmaceuticals and health care. After political work in the Swedish parliament, Marianne started a successful PR agency in 1994 that handled large national and international assignments such as crisis management, product launches, lobby campaigns, IPOs and brand campaigns. She and the agency have received several awards for, among other things, attitude campaigns in health.
  • Other ongoing assignments:Peptonic Medical AB (publ), 1.6 million club AB, First Communication AB and Effektiv Media i Stockholm Aktiebolag.
  • Holdings: 293 800 shares and 100 000 warrants.

Independent in relation to the Company and its management and the Company's major shareholders.

TOM RÖNNLUND

Board member
Board member since Ocotber 2023
Tom_beskuren

  • Born: 1972
  • Education: Master of Business Administration, Stockholm University
  • Experience: Tom has extensive experience as a CEO/General Manager in the medical technology, medical device, pharmaceutical and healthcare industries. His experience includes leadership, strategy, commercialisation, business development and financing from public and private companies. In addition to operational roles at Probi AB, Navamedic ASA, IMS Health, Bristol Myers Squibb and Eli Lilly, he also has extensive board experience from the Nordic and international business community.
  • Other ongoing assignments: Chief Commercial Officer - Surgify Medical Oy and board member of Bonnier Healthcare AB and Redwood Pharma AB (publ).
  • Holdings: 100 000 shares and 50 000 warrants. 

TOMAS ERIKSSON

Board member
Board member since Ocotber 2023
Tomas Eriksson photo

  • Born: 1964
  • Education: Fil Kand Lunds University
  • Experience: Extensive experience in leadership roles and as a mentor/coach for early-stage companies in life sciences. CEO of Sinntaxis Ltd, which is working on a repositioned drug candidate aimed at improving brain recovery after stroke. More than a decade of experience as co-founder and CEO of A1M Pharma (now Guard Therapeutics), including 7 years as CEO of a listed company developing a biological drug to protect the kidneys against oxidative stress. Before that, 15 years of experience in international marketing and sales of medical technology and diagnostics.
  • Other ongoing assignments: Chairman of the Board Omnio AB, CEO Sinntaxis AB
  • Holdings: No holdings 

Independent in relation to the Company and its management and the Company's major shareholders.